T-cell therapy for recurrent brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests modified immune T-cells to treat recurrent glioblastoma (a fast-growing brain tumor) that can be seen on scans. Because it’s early-stage, the goal is mainly safety, but you may be helping researchers understand if the treatment can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 70 years old
- You have recurrent glioblastoma (or another measurable brain tumor) after standard treatment
- You can join the study paperwork and follow the study team’s instructions
- Your steroid dose is low or you’re not taking dexamethasone (≤ 4 mg per day, if used)
- Your health tests are adequate (blood counts, liver, and kidney) and you have enough lymphocytes
- Your heart function is acceptable, and you’re expected to live more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This early-stage study tests a treatment made from your tumor’s immune cells (TILs) to help shrink brain glioma. You may be considered if your glioma is back or has spread and standard options are no longer working (or don’t exist).
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Hear when a new Glioblastoma Multiforme of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.